Answers are grounded in this paper and cite their sources.
Introduction Mesenchymal stem cells (MSCs) are the most widely investigated cellular therapeutic in regenerative medicine. There is an increased interest in cryopreserved over-the-counter products in clinical practice. The thawing step, although often treated as trivial, has emerged as a critical determinant of post-thaw viability, immunomodulatory potency, and ultimately therapeutic efficacy. Methodology This review compares major clinical thawing techniques. These include 37 °C water bath, automated dry-warming devices, slow rewarming, body-temperature thawing, and vitrification rewarming and supplements. This review compares detailed numerical data from the primary studies using viability percentages, fold-changes, and clinical efficacy estimates. A substantially expanded source-comparison section synthesizes head-to-head data on bone marrow adipose-derived umbilical cord/Wharton’s jelly (UC/WJ), placental, and other mesenchymal stem cell sources. Results According to the previously conducted studies, UCMSCs demonstrated promising post-thaw viability (∼81% with standard 10% dimethyl sulfoxide) and favorable proliferative recovery in several studies. However, direct and standardized comparisons across MSC sources remain limited. ADMSC survival during freeze–thaw (notable loss of α4-integrin and CFU-F counts) is comparatively less than other sources. However, they exhibit the strongest immunosuppressive secretome. BMMSCs have been used extensively in clinical research and produce the most consistent angiogenic effect. However, they are cleared from the lungs faster than UCMSCs or ADMSCs. Conclusion We provide a practical, evidence-based protocol and identify potential interventions for clinical sites adopting cryopreserved MSC programs.
No takes yet. Share an insight, caveat, or question.
Habiba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: